1.
A 56-year-old male comes to see you to discuss adjuvant chemotherapy for his recently diagnosed T3 N0 Colon cancer that has been surgically removed. The tumor was located in the left colon.
On his pathology report, it is found to be a T3 N0 adenocarcinoma. The surgical margins are negative. It is a grade II tumor, there is no evidence of LVI or PNI and all 14 lymph nodes that are removed are negative for cancer involvement. Further tumor analysis reveals that the cancer is MSI-H. Given that the tumor is MSI-High, what does it tell one regarding the efficacy of adjuvant therapy for him?
A . He will benefit from receiving Bevacizumab
B . He will benefit from receiving just 5-FU
C . He will benefit from receiving FOLFOX
D . He will not benefit from 5-FU therapy
E . He will not benefit from Bevacizumab
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) He will not benefit from 5-FU therapy
The benefit of adjuvant chemotherapy for patients with Stage II Colon cancer is marginal. The NCCN panel believes that it is reasonable to accept the relative benefit of adjuvant therapy in Stage III disease as indirect evidence of benefit for Stage II disease, especially for those patients with high-risk features.
The QUASAR trial demonstrated a small benefit in OS for patients with Stage II disease treated with 5-FU/LV compared to patients not receiving adjuvant therapy (RR of recurrence at 2 years, 0.71; P=.01). In this trial though, 64% of patients had fever than 12 lymph nodes samples and may have been patients with higher risk disease who were more likely to benefit from adjuvant therapy.
Colon cancer patients with Stage II disease who have high-levels of microsatellite instability (MSI-H) or defective DNA mismatch repair have a good prognosis and do not benefit from 5-FU chemotherapy.
A group of investigators examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer.
MSI assay or immunohistochemistry for MMR proteins were performed on 457 patients who were previously randomly assigned to FU-based therapy (either FU + levamisole or FU + leucovorin; n = 229) versus no postsurgical treatment (n = 228). Data were subsequently pooled with data from a previous analysis. The primary end point was disease-free survival (DFS).
Overall, 70 (15%) of 457 patients exhibited dMMR. Adjuvant therapy significantly improved DFS (HR=0.67; P = .02) in patients with pMMR tumors. Patients with dMMR tumors receiving FU had no improvement in DFS (HR, 1.10; P = .85) compared with those randomly assigned to surgery alone. In the pooled data set of 1,027 patients (n = 165 with dMMR), these findings were maintained; in patients with stage II disease and with dMMR tumors, treatment was associated with reduced overall survival (HR, 2.95; P = .04).
**Pearl: 15% of sporadic tumors are MSI
**Pearl: MSI-H tumors are often right-sided, have undifferentiated histology, present as stage II, and more
often in females
**Pearl: Poorly differentiated histology is not considered a high-risk feature for patients with Stage II disease
whose tumors are MSI-High
Reference: Sargent DJ et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28(20): 3219-26
2.
A 19-year-old male was recently diagnosed with Good risk, Stage IIB (S1) NSGCT. Four weeks ago, he underwent an orchiectomy for a right testicular cancer. Pathology revealed that he had a nonseminoma. He was referred over to see Medical Oncology.
His post-orchiectomy AFP was 145 ng/ml. This was repeated 1 week later and it has increased to 175 ng/ml. CT imaging revealed 4 cm mass in the right retroperitoneum. He started his first cycle of BEP. Bleomycin is being given 30 units weekly. Three days after finishing his 1st cycle of therapy (Day 1, 8, 15 of bleomycin, and days 1-5 of etoposide and cisplatin), he develops dyspnea and a dry cough.
Chest imaging confirms pneumonitis from his bleomycin. He partially recovers from this episode and comes to see you to discuss initiation of his second cycle of therapy; the plan was to administer BEP x 3 cycles. What should be recommended?
A . Give bleomycin at full dose
B . Give bleomycin at a 25% dose reduction
C . Give bleomycin at a 50% dose reduction
D . Do not give bleomycin. Substitute ifosfamide instead
E . Give EP alone for 3 more cycles
Your Answer : Option
Not Answered
Correct Answer : Option
E
Explanation:E) Give EP alone for 3 more cycles
For patients with Stage IIB (S1) NSGCT, one can offer either BEP x 3 cycles or EP x 4 cycles.
As he has developed bleomycin lung toxicity, one should not risk offering more Bleomycin. One would not want him to develop pulmonary fibrosis which can be fatal. EP x 4 is a perfectly acceptable regimen. As he had 1 cycle of BEP already (and therefore EP x 1), one can give him 3 more cycles of EP and then stop therapy.
Bleomycin pulmonary toxicity can often start off as pneumonitis but can eventually progress to the development of fibrosis. The incidence of bleomycin-induced pulmonary fibrosis can be as high as 10%. After stopping the drug, one can administer high-dose steroids to help the treat the inflammation.
**Pearl:
If a patient has Intermediate- or Poor-risk Nonseminoma, one can substitute Ifosfamide for Bleomycin. This is known as the VIP regimen. It is mostly offered to patients who have a contraindication to receive Bleomycin.
Reference: Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48(1): 92-94
3.
A 72-year-old male has started palliative chemotherapy with Gemcitabine + Nab-Paclitaxel for his Stage IV Pancreatic cancer. He was diagnosed over 3 months ago with metastatic pancreatic cancer. Baseline imaging revealed that he had several liver metastases. A biopsy of a liver lesion confirmed the diagnosis. He started therapy with this chemotherapy regimen and on restaging scans he was found to have a partial response with 60% reduction of his liver lesions. He has tolerated therapy very well thus far. Of note, Next generation sequencing revealed no targetable lesions including no mutation in BRCA1 or BRCA2.
The patient acutely developed an acute onset of fatigue and dehydration. He presented to the ED and was found to have acute renal failure. Labs reveal a Hb of 7.4 g/dl and the platelet count is 72,000 per mL. Cr is 3.2 mg/dl. PT and PTT are WNL. A smear is reviewed and shows lots of schistocytes. What is the most likely etiology for this patient’s acute clinical worsening?
A . DIC from Pancreatic cancer
B . HUS from Gemcitabine
C . Trousseau's Syndrome
D . ATN from Nab-Paclitaxel
E . Stauffer's Syndrome
Your Answer : Option
Not Answered
Correct Answer : Option
B
Explanation:B) HUS from Gemcitabine
Gemcitabine is a Pyrimidine analog. It is metabolized within cells to the active nucleoside forms: diphosphate and triphosphate. Gemcitabine diphosphate inhibits ribonucleotide reductase. Gemcitabine triphosphate competes to be incorporated into DNA. In doing so, DNA synthesis is halted.
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure.
In this condition, one will oftentimes see an elevated LDH, low haptoglobin and schistocytes on the peripheral blood smear. A renal biopsy would show microvascular damage of the arterioles and small arteries occluded by eosinophilic hyaline thrombi containing fibrin and platelet aggregate.
Several etiologies that can cause this condition include cancers, chemotherapy drugs and infections.
The mechanism of gemcitabine-induced HUS is unclear. Some posit that this chemotherapy medication may lead to microvascular endothelial damage or immunocomplex deposition.
There is no consensus as to the best treatment for Gemcitabine related HUS.
However, one should immediately discontinue gemcitabine if HUS is seen. Other potential therapies include steroids, FFP administration, plasmapheresis or hemodialysis; it is unclear how well these therapies work.
**Pearl: Mitomycin C can also cause HUS
Reference: Muller S. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 2005;84(2): 110-4.
4.
A 62-year-old female is s/p TAH/BSO, comprehensive surgical staging and optimal debulking for a recently diagnosed left-sided ovarian cancer. Final pathology reveals a Malignant Mixed Mullerian tumor. She is found to have stage II disease. CT imaging reveals no signs of metastatic disease.
Her CA-125 is 12 U/ml. She is in very good health with no comorbid medical conditions. What should be offered as adjuvant therapy?
A . Observation
B . IP Cisplatin and IP/IV Paclitaxel chemotherapy
C . Adjuvant chemotherapy with Adriamycin + Ifosfamide x 6 cycles
D . Adjuvant Gemcitabine + Docetaxel x 6 cycles
E . Adjuvant Carboplatin + Paclitaxel x 6 cycles
Your Answer : Option
Not Answered
Correct Answer : Option
E
Explanation:E) Adjuvant Carboplatin + Paclitaxel x 6 cycles
Carcinosarcomas consists of malignant epithelial and mesenchymal components. They
account for < 2% of malignant ovarian cancers. These are rare tumor that carry a poor
prognosis.
Many pathologists consider these tumors to be a variant of poorly differentiated epithelial ovarian cancer
[metaplastic carcinoma].
Patients with carcinosarcomas are not candidates for fertility-sparing surgery regardless of the age
or stage. Optimal surgical debulking is recommended for patients with this type of ovarian cancer.
Patients with carcinosarcomas should be treated with adjuvant Carboplatin/Taxol. This is the preferred
adjuvant chemotherapy option.
Ovarian Carcinosarcoma:
Stage I-IV: Patients should be offered chemotherapy with Carboplatin + Taxol
One can substitute Docetaxel or Liposomal Doxorubicin for Taxol
Although not preferred, the following are the other adjuvant chemotherapy options that can be offered to patients
who have Ovarian Carcinosarcoma:
--Carboplatin + Ifosfamide
--Cisplatin + Ifosfamide
--Paclitaxel + Ifosfamide
Reference: Leiser AL et al. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007;105(3):657-61
5.
A 59-year-old female has recently undergone a maximal complete resection for a left parietal lobe brain tumor. Neurosurgery performed the surgery and was able to remove all of the tumor.
Final pathology reveals a WHO Grade 3 Oligodendroglioma. Further analysis of the tumor specimen reveals codeletion of 1p9q and IDH is mutated. A Brain MRI done 2 days after surgery confirms all the tumor has been surgically removed. Her Karnofsky performance status is >90. What adjuvant therapy should be offered?
A . Standard Radiation
B . Standard Radiation with BCNU wafer
C . Chemotherapy with Temozolamide
D . Standard Radiation therapy and neoadjuvant or adjuvant Lomustine, Procarbazine, and Vincristine (PCV) chemotherapy
E . Observation
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Standard Radiation therapy and neoadjuvant or adjuvant Lomustine, Procarbazine,
and Vincristine (PCV) chemotherapy
Anaplastic oligodendrogliomas are chemotherapy-sensitive tumors. A phase III study (EORTC 26951) evaluated the addition of adjuvant PCV x 6 cycles with RT vs. RT alone (59.4 Gy). A total of 368 patients were enrolled. The overall survival favored the RT/PCV group (42.3 vs. 30.6 mo; HR=0.75).
In the 80 patients whose Glioma harbored a 1p/19q codeletion, the overall survival favored PCV arm (Not reached vs. 112 mo; HR=0.56). IDH mutational status was also of prognostic significance.
Gliomas that harbored the 1p/19q codeletion had a better prognosis.
RTOG 9402 randomized 291 patients with anaplastic oligodendroglioma or anaplastic oligoastrocytoma to PCV followed by immediate RT or RT alone. No difference in the median Overall survival was seen between either arm (4.6 years vs. 4.7 years; P=0.10). However, an unplanned subgroup analysis of the 126 patients whose tumors were 1p19q co-deleted found a doubling in median Overall survival (14.7 vs. 7.3 years; HR=0.59; P=0.03) when PCV was added to RT as upfront treatment.
The NCCN panel recommends that PCV be administered after RT (as per EORTC 26951) since the intensive PCV regimen given prior to RT (RTOG 9402) was not tolerated as well.
The phase III CODEL study was designed to assess the efficacy of Temozolomide for the treatment of newly diagnosed anaplastic [Grade III] Oligodendrogliomas. The study was redesigned to compare RT + PCV to RT + Temozolomide in patients with anaplastic oligodendroglioma as well as low-grade oligodendroglioma. Results of this important study are pending.
Of note, the 2016 WHO classification of tumors of the CNS has deleted oligoastrocytoma as a category.
https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Reference: Van den Bent MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 2013;31(3):344-50
6.
A 48-year-old male who is a 40-pack-year smoker comes to see you to discuss therapy for his limited stage small cell lung cancer. Staging reveals no distant metastasis and his Brain MRI is negative. He has a robust performance status. What treatment do you propose?
A . Lobectomy followed by adjuvant Carboplatin/Paclitaxel
B . Concurrent chemoradiation with Carboplatin/Etoposide (radiation given in daily fractions), followed by PCI
C . Concurrent chemoradiation with Cisplatin/Etoposide (radiation given in bid fractions), followed by PCI
D . In a sequential manner, give chemotherapy with Cisplatin/Etoposide followed by radiation therapy. No brainvradiation is indicated as the brain MRI is negative
E . None
Your Answer : Option
Not Answered
Correct Answer : Option
C
Explanation:C) Concurrent chemoradiation with Cisplatin/Etoposide (radiation given in bid fractions), followed by PCI
Cisplatin/Etoposide is preferred over Carboplatin/Etoposide for concurrent therapy for patients with limited stage disease. For extensive stage (chemotherapy alone), one can offer either Carboplatin or Cisplatin. This is an important distinction.
A seminal study (See the reference below) demonstrated that twice a day (hyperfractionated) radiation confers a benefit over daily radiation:
--45 Gy in 3 weeks (1.5 Gy bid) > 45 Gy in 5 weeks (1.8 Gy daily)
--5-year OS 26% with bid XRT vs. 16% for daily RT (P=0.04)
However, these doses were not biologically equivalent so this created some measure of controversy.
When BID fractionation is used, there should be at least a 6-hour interfraction interval to allow for repair of normal tissue. If one is using once-daily RT, higher doses of 60-70 Gy should be used.
RTOG 0538 will hopefully shed light on how Radiation should be optimally administered.
This study is evaluating the following:
1) Administering RT 45 Gy in 30 treatments (bid in 3 weeks)
2) 70 Gy in 35 treatments (7 weeks)
3) 61.2 Gy given in 34 treatments (daily x 3 weeks, then bid x 2 weeks; this arm has been discontinued)
Of note, the randomized, phase III European CONVERT trial did not demonstrate superiority of 66 Gy (once daily) over 45 Gy (BID), but overall survival and toxicity were comparable.
Corinne Faivre-Finn et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncology 2017.
Reference: Turrisi AT et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340(4):265-71
7.
A 52-year-old female is undergoing treatment for her stage IV melanoma. Baseline imaging revealed that she had both lung and liver lesions. The index liver lesion measures 3 cm in size. Biopsy of this lesion reveals a BRAF wild-type melanoma. A baseline brain MRI was negative.
She was initially started on Nivolumab as frontline therapy and achieves a partial response. However, after 1 year of treatment she developed progression of her disease.
A restaging CT scan shows that the liver lesion measures 4.5 cm in size. She has 2 new lung lesions. She is started on Ipilimumab 3 mg/kg and the patient has had 2 cycles of treatment. Thus far, she has tolerated treatment well outside of having Grade 1 diarrhea.
She presented to a local ED for some vague abdominal pain and bloating. A full workup is performed and is negative. Her CMP, Amylase, Lipase and Abdominal X-ray are all negative. She has a CT scan with IV contrast performed and it that reveals that all the lesions are stable except that her index liver lesion has increased from 4.5 to 5 cm over the span of 6 weeks. What should be recommended?
A . Stop Ipilimumab and switch to Pembrolizumab
B . Increase the dose of Ipilimumab to 10 mg/kg
C . Continue therapy
D . Switch to Nivolumab + Relatlimab
E . Add Dacarbazine to Ipilimumab
Your Answer : Option
Not Answered
Correct Answer : Option
C
Explanation:C) Continue therapy
The patient in this question has just started on immunotherapy with Ipilimumab. It would be premature to assume that the slight enlargement of her liver lesion represents true tumor progression. This patient should be continued on therapy. Responses to immunotherapy can sometimes be delayed.
It can take time before once sees a cancer respond to immunotherapy. One needs to be careful with stopping therapy too soon based on an interval CT imaging. Sometimes, responses can occur even after radiologic evidence of initial disease progression. Pseudo-progression refers to cancer deposits that initially appears larger on a scan, perhaps due to the infiltration of the immune cells at the tumor location, but will eventually regress with time. The patient had a CT scan performed to evaluate her abdominal pain. It was not a definitive restaging scan and this CT scan took place after her only received 2 doses of Ipilimumab.
Ipilimumab is a humanized monoclonal IgG1 antibody that targets the Cytotoxic T-lymphocyte antigen-4 (CTLA-4). CTLA-4 on T cells acts as a break for the normal immune system. By blocking CTLA-4, Ipilimumab unleashes the immune system leading to T-cell activation.
This drug attained FDA approval in 2011 as monotherapy (3 mg/kg) x 4 cycles for patients with unresectable or metastatic melanoma (both pre-treated or chemotherapy naïve patients).
Reference: Graziani G et al. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 2012;65(1):9-22.
8.
Two years ago, a 56-year-old female had a large macular lesion located on her right upper back that had been progressively growing. She was referred to Dermatology who performed a biopsy of this lesion. Pathology revealed that the tumor was CD34+. Further evaluation confirmed that she had a Dermatofibrosarcoma protuberans (DFSP).
The patient undergoes excision of this tumor with Mohs and achieved negative margins. No adjuvant therapy is given. She was disease free for 2 years until she recently developed dyspnea. Her Oncology team ordered a CT scan of the Chest. She was found to have over 12 lung lesions. One of these lung lesions is biopsied confirming DFSP. Further testing of the sarcoma reveals a t(17;22). Which therapy should be offered?
A . Hospice
B . Imatinib
C . Cisplatin + Etoposide
D . Carboplatin + Paclitaxel
E . Pembrolizumab
Your Answer : Option
Not Answered
Correct Answer : Option
B
Explanation:B) Imatinib
Dermatofibrosarcoma protuberans (DFSP) is a tumor that occurs of the dermis layer of the skin.
Up to 5% of these tumors can metastasize. These tumors can initially appear as a bruise or pimple. Over 90% are slow growing tumors. A subset of DFSP can harbor a high-grade sarcomatous component.
The majority (>90%) will have t(17;22). This translocation fuses the collagen gene (COL1A1) with the platelet-derived growth factor (PDGF) gene; this results in a fusion protein that leads to a potent growth factor (PDGFRB).
The primary treatment is surgery to achieve negative margins. Surgical approaches include:
Excision with other forms of peripheral and deep en face margin assessment [PDEMA]
Mohs Micrographic surgery
If PDEMA is unavailable, consider wide excision
Phase II data of imatinib in patients with locally advanced or metastatic DFSP revealed an objective response rate of almost 50%. The median time to progression was 1.7 years.
Imatinib is approved b the FDA for the treatment of unresectable, recurrent, and/or metastatic DFSP in adult patients.
Of note, patients with unresectable (but locoregional) DFSP can be offered neoadjuvant imatinib in hopes of downstaging the tumor to enable resection.
Reference: Rutkowski P et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28(10):1772-9.
9.
A 48-year-old female presents with a left-sided neck mass that has been getting progressively largely over the past 6 months. She is in overall good health and has no known medical conditions. Her primary care physician performs a thorough workup and orders a neck ultrasound that reveals a 2 cm left cervical lymph node that appears concerning for malignancy.
The patient is set up for an incisional biopsy that reveals that she has a grade I follicular lymphoma. She is referred to Oncology who performs a bone marrow biopsy that is negative for lymphoma involvement. A PET-CT scan shows only FDG activity at this solitary left-sided neck lymph node. She is felt to have stage I disease. What should be offered as therapy?
A . Observation
B . R-CHOP
C . R-CVP
D . Radiation therapy
E . Lenalidomide and Rituximab
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Radiation therapy
Generally speaking, follicular lymphomas do not present in a localized manner. When they do, one should consider local therapy with radiation as some studies show that this can lead to a long-term remission.
Observation, single agent Rituximab, Rituximab/Lenalidomide or Rituximab (or Obinutuzumab) + chemotherapy are also options to consider.
On study retrospectively evaluated the effectiveness of radiation in 177 patients with stage I or II follicular small cleaved-cell and follicular mixed small cleaved-cell and large-cell non-Hodgkin's lymphoma. Radiotherapy doses ranged from 35 to 50 Gy. The median survival time was 13.8 years. At 20 years, 37% patients were relapse-free. Only five of 47 patients who reached 10 years without relapse subsequently developed recurrence.
The NCCN guidelines listed ISRT as the preferred therapy for patients with Stage I or contiguous Stage II Follicular lymphoma that is grade 1-2.
Reference: Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14(4):1282-90.
10.
A 59-year-old female with Chronic Phase CML has been on imatinib 400 mg daily for 18 months. Baseline evaluation revealed good-risk disease on the Hasford scoring system. During her 12-month evaluation, she was shown to have a MMR.
During her 18-month evaluation, the Bcr-Abl transcript has increased to 12% and FISH testing showed the presence of t(9;22). A bone marrow biopsy is performed and she has a cytogenetic relapse. Three of 20 metaphases harbor Ph+. She has been compliant with imatinib and has not been on any other medications. Mutational analysis of the BCR-ABL kinase domain reveals F317L. What do you recommend?
A . Increase Imatinib to 800 mg daily
B . Immediate Allogeneic SCT
C . Continue therapy, but recheck cytogenetics in 3 months
D . Continue therapy, but add Interferon to Imatinib
E . Switch to a different TKI
Your Answer : Option
Not Answered
Correct Answer : Option
E
Explanation:E) Switch to a different TKI
This patient has relapsed disease. This is defined by any of the following:
--Any sign of loss of Hematologic response
--Any sign of loss of CCyR or its molecular response correlate defined as an increase in BCR-ABL1
transcript to >1%
--1-log increase in BCR-ABL1 transcript levels with loss of MMR
At the 18-month follow-up mark, to see a cytogenetic relapse is disconcerting. According to the NCCN guidelines, having a BRC-ABL1 > 10% at the 3-month mark (or greater) connotes TKI resistance.
In situations like this, one needs to check for compliance of the TKI and other drug-drug interactions. Prior to switching therapy for a presumed TKI failure, one should check the mutational status of BCR-ABL. For second-line treatment for patients with TKI-resistant disease, one should switch to another alternate TKI that is tailored to the results of the BCR-ABL1 mutation testing. These patients should also be evaluated for an allogeneic HCT.
There is a subset of BCR-ABL mutant clones associated with impaired responses to second-generation TKIs.
As an example, for patients who harbor a F317L mutation in BCR-ABL1, one would offer Nilotinib over Dasatinib or Bosutinib. If a patient has a G250E mutation, one would offer Dasatinib or possibly Nilotinib.
The Mutational status of BCR-ABL1 will inform on which TKIs may work:
E255K/V, F317V/I/C, F359V/C/I, T315A, Y253H: Use Bosutinib
T315I: Use Ponatinib, Asciminib, Omacetaxine, Allogeneic transplant
V299L, T315A, F317L/V/I/C: Use Nilotinib
Y253H, E255K/V, F359V/C/I: Use Dasatinib
The following mutations confer resistance to the following TKIs:
--Bosutinib will not work if a patient has a BCR-ABL1 mutation in T315I, V299L, G250E or F317L
--Dasatinib will not work if a patient has a BCR-ABL1 mutation in T315I/A, F317L/V/I/C or V299L
--Nilotinib will not work if a patient has a BCR-ABL1 mutation in T315I, Y253H, E255K/V, F359V/C/I
https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
Reference: Jabbour E et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117(9):1800-11
11.
A 42-year-old female was recently diagnosed with likely stage II right breast cancer. On routine mammogram, she was found to have a 3 cm right-breast mass with no clinical evidence of axilla LAD. Genetic testing reveals that she harbors a BRCA1 mutation.
The patient undergoes a biopsy of the 3 cm mass and the results are pending. Which of the following is the most likely type of breast cancer that she has?
A . ER+, PR+, Her2-
B . ER+, PR-, Her2-
C . ER+, PR+, Her2+
D . ER-, PR-, Her-
E . ER-, PR-, Her2+
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) ER-, PR-, Her-
Hereditary breast ovarian cancer syndromes are autosomal dominant disorders. BRCA1 and BRCA2 are tumor suppressor genes whose role is to control cell growth and cell death. Mutations in these genes disenable this function leading to an increased cancer risk.
There are several differences between BRCA1 and BRCA2 related tumors.
BRCA1-related breast cancers are mostly triple negative.
BRCA2 breast cancers are mostly ER+
BRCA1: On chromosome 17
50-85% risk of female breast cancer. 40% risk of ovarian cancer
40-60% lifetime risk of developing a second breast cancer
BRCA2: On chromosome 13
40-60% risk of female breast cancer. 6% risk of male breast cancer
10-15% risk of ovarian cancer
Increased risk of stomach, melanoma, prostate, pancreatic cancer (along possibly with others)
Reference: Hirshfield KM, Ganesan S. Triple-negative breast cancer: molecular subtypes and targeted therapy. Curr Opin Obstet Gynecol 2014;26(1):34-40
12.
A 45-year-old female with thyroid cancer is being evaluated for possible adjuvant treatment with Radioactive Iodine therapy. Recently, she had a total thyroidectomy for a Papillary thyroid cancer. She was found to have a unifocal, 1 cm classic papillary thyroid cancer with no vascular invasion or extrathyroid extension. Her post-operative unstimulated thyroglobulin is < 1 ng/mL. She has no detectable anti-Tg antibodies. She had no lymph nodes involved or distant metastases. What is true regarding RAI treatment in her case?
A . She needs RAI as her age is a poor prognostic risk factor
B . Her tumor meets all the criteria not to offer RAI therapy
C . She does not need RAI as it is only given for patients with differentiated thyroid tumors measuring > 5 cm in size or who have positive lymph node involvement
D . She needs RAI as her gender puts her at a higher risk of developing a recurrence
E . She does not need RAI as she had a thyroidectomy
Your Answer : Option
Not Answered
Correct Answer : Option
B
Explanation:B) Her tumor meets all the criteria not to offer RAI therapy
RAI as adjuvant therapy is not offered to every patient with differentiated thyroid cancer. The size cutoff to offer it is often 4 cm in size, which she clearly is not close to having. All of her clinical and pathologic features are favorable so one would not offer her adjuvant RAI.
RAI does have toxicity, so you need to carefully evaluate if a patient will truly benefit from it as adjuvant therapy.
RAI is typically recommended if any of the following features are present:
1) Gross extrathyroidal extension
2) Primary tumor >4 cm
3) Postoperative unstimulated Tg> 10 ng/mL
4) Bulky or >5 positive lymph nodes
If a patient has a differentiated thyroid cancer, one would selectively recommend adjuvant RAI if any of the following features are seen:
Tumor 2-4 cm
High risk histology (ie, poorly differentiated, tall cell, columnar cell, hobnail variant, diffuse sclerosing, and insular)
Lymphatic invasion
Vascular invasion
Cervical lymph node metastases
Macroscopic multifocality (one focus > 1 cm)
Postoperative unstimulated thyroglobulin < 10 ng/mL
Microscopic positive margins
Detectable anti-Tg antibodies
RAI is not typically recommended if all of the following are present:
--Classic papillary thyroid cancer
--Largest primary tumor <2 cm in size
--Intrathyroidal
--Unifocal or multifocal (all foci ≤ 1 cm)
--No detectable anti-Tg antibodies
--Postoperative unstimulated Tg < 1 ng/mL
--Negative postoperative ultrasound, if done
Reference: Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006;94(8):692-700.
13.
A 35-year-old male presents to see a Hematologist for an evaluation of a possible iron disorder. The patient has been had been having worsening fatigue over the past 6 months. He went to see his PCP who performs a workup. His CBC with Plt/Diff is largely unrevealing. Iron studies were abnormal. His ferritin is elevated at 850 μg/L. His transferrin saturation is normal at 20%. The patient is sent to see a Hematologist.
LFTs showed transaminitis. An Ultrasound showed some abnormal findings. A dedicated Liver MRI was done and it does suggest iron loading in the liver. A liver biopsy is performed and the patient is found to have iron accumulation in the hepatic Kupffer cells.
He has no signs of end organ damage to the heart, endocrine glands or joints. He has 4 siblings, 2 of whom have the same type of disorder. This patient likely has a mutation in which of the following genes?
A . HFE
B . FPN
C . HJV
D . TfR2
E . HAMP
Your Answer : Option
Not Answered
Correct Answer : Option
B
Explanation:B) FPN
Ferroportin Disease (FD) is an autosomal dominant hereditary iron loading disorder associated with heterozygote mutations in the ferroportin-1 (FPN) gene. Ferroportin’s role in the body is to transfer iron from the intestine and macrophages into the bloodstream.
There appear to be two different phenotypes of Ferroportin disease.
Macrophage type:
Loss-of-function mutations of ferroportin are thought to produce a molecule that either does not traffic appropriately to the cell surface or that has limited ability to export iron.
This results in excess accumulation of iron in macrophages, with resulting high serum ferritin, normal to reduced transferrin saturation (TSAT), and mild anemia. In young females, hypochromic microcytic anemia may develop that is responsive to iron supplementation. This has also been called macrophage-type (M-type) and is now considered the real ferroportin disease, which is no longer included among HH because of the distinct phenotype.
Hepatic-type (Non-classical):
Gain-of-function mutations produce a ferroportin protein that is resistant to hepcidin and retains full iron export capability. The mutation may affect the binding site for hepcidin (C326) or occurs in its proximity. Iron overload is similar to classic HH.
This results in increased TSAT, high levels of ferritin and hepcidin, and hepatic iron overload, similar to or more severe than classical HH. Liver biopsy has shown increased hepatocyte iron. In ferroportin disease, unlike classical hemochromatosis, the iron is considerably more prominent in Kupffer cells than in hepatocytes, and fibrosis is primarily sinusoidal.
Ferroportin is the iron transport channel mainly expressed in macrophages and hepatocytes and on the basolateral surface of intestinal enterocytes that is blocked by hepcidin. Ferroportin has also been implicated in the transport of other ions such as manganese.
So, in the Macrophage type (ie, classical), mutations in FPN1 limit but does not impair the iron export in enterocytes, but it does severely affect the iron transfer in macrophages. This leads to iron trapping in tissue macrophages with reduced iron release to serum transferrin. Hence, patients with this disease have low transferrin saturation. They will often have normal/low transferrin saturation, mild anemia and mild organ disease.
A hallmark feature of this variant of Ferroportin disease is marked iron accumulation in hepatic Kupffer cells, but not as much iron accumulation in the hepatocytes. This is opposite to what is seen in classical hemochromatosis.
The differential diagnosis for this condition includes hereditary hemochromatosis, the syndrome commonly due to either HFE, TfR2, HJV, HAMP or gain of function mutation in FPN1. However, in these conditions, the elevated ferritin levels is seen in concert with a high transferrin saturation, iron-spared macrophages, and progressive liver parenchymal cell iron load.
These conditions (HFE, TfR2, HJV, HAMP or non-classical FPN1) share a similar pathogenic basis (lack of hepcidin function-activity), biochemical expressivity (high transferrin saturation and high serum ferritin), liver pathology features (iron accumulation in parenchymal cells with iron-spared Kupffer cells until late stage), damage and disease of distinct target organs (liver, heart, endocrine glands, joints).
An abdominal MRI for patient’s with Ferroportin disease can show iron loading in the spleen, spine and liver.
A non-aggressive phlebotomy regimen is recommended, with careful monitoring of the transferrin saturation and hemoglobin due to the risk of anemia. Family screening is mandatory since siblings and offspring have a 50% chance of carrying the pathogenic mutation.
Of note, non-classical Ferroportin disease occurs with mutations in ferroportin that are resistant to inhibition by the iron regulatory molecule hepcidin, retaining full iron export capability. Patients will normally have high levels of ferritin and hepcidin, increased transferrin saturation, and typical deposition of iron in the hepatic parenchyma. This has also been called hepatic-type ferroportin disease.
https://www.uptodate.com/contents/hfe-and-other-hemochromatosis-genes?search=ferroportin%20disease§ionRank=1&usage_type=default&anchor=H16&source=machineLearning&selectedTitle=1~17&display_rank=1#H16
Reference: Antonello Pietrangelo et al. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 2017 Dec; 102(12): 1972–1984
14.
A 62-year-old male is currently admitted to the hospital for anemia due to bleeding. The patient was recently found to have cholecystitis. He was taken for a cholecystectomy.
On POD#1, the patient developed worsening right-sided purpura near his abdomen. Is Hemoglobin was drawn and it was found to be 6.2 g/dl, which was done from a preoperative level of 12 g/dl. Imaging is performed and he was found to have a large retroperitoneal bleed. He was surgically explored and the bleeding vessel that was causing the bleeding was fixed.
Hematology is consulted as the patient needs several pRBC transfusions but the patient carries a history of IgA deficiency. How should the pRBC be modified to ensure that he receives a safe transfusion?
A . No specific intervention needed. IgA deficiency poses no risk for the patient to receive pRBC transfusions
B . Just administer premedications with steroids prior to him receiving the pRBC transfusion
C . Gamma irradiate the blood products prior to the transfusion
D . Wash the pRBC product prior to the transfusion
E . Leukoreduce the pRBC products
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Wash the pRBC product prior to the transfusion
IgA is concentrated mostly in the mucosal secretions and is believed to be important in the immune function of the mucosal barrier.
A minority of IgA-deficient individuals are symptomatic. These patients may develop recurrent sinopulmonary infections, autoimmune disorders, gastrointestinal disorders, allergic diseases and rare anaphylactic reactions to blood products.
There are two levels of severity of IgA deficiency that is recognized. A serum IgA level < 7 mg/dL is considered to represent a severe deficiency.
IgA deficiency is the most common human immunodeficiency. The presence of anti-IgA that occurs in an IgA deficient recipient can lead to anaphylaxis if blood products are administered. This occurs as the anti-IgA antibody of the host reacts against the IgA antigen seen on the donor red cell units.
Most patients with selective IgA deficiency do not form anti-IgA antibodies. These antibodies are usually only found in patients who have undetectable serum IgA.
Patients with selective IgA deficiency can develop urticaria, wheezing, shock and cardiac arrest after receiving transfusions. If this were to happen, one must stop the transfusion immediately. Patients may need Epinephrine. One critical point is that patients with IgA deficiency who are transfused with plasma products that carry IgA, will have an _immediate_ reaction to the blood product.
Patients with severe IgA deficiency can experience infusion reactions to blood products containing small amounts of IgA, typically in plasma including the following products: Whole blood, Red blood cells, Granulocytes, Platelets, FFP, Cryoprecipitate and IVIG.
By washing the donor red cell units with saline, centrifuge or removal of the supernatant, the IgA antibodies will be removed. However, this will shorten the shelf-life of red blood cells to less than 24 hours.
Indications to wash Red blood cells:
--Severe allergic reactions
--Removal of maternal antibodies for fetal transfusion
(Hemolytic disease of newborn, Neonatal alloimmune thrombocytopenia)
**Pearl:
Patients who should be screened for anti-IgA antibodies are those patients with severe sIgAD and in patients with partial sIgAD who have experienced an infusion reaction to a blood product in the past. Screening for anti-IgA antibodies allows clinicians to identify patients at risk for infusion reactions and helps these patients become informed about the potential risks of receiving blood products.
https://www.uptodate.com/contents/selective-iga-deficiency-management-and-prognosis?search=febrile%20non-hemolytic%20reaction&topicRef=7947&source=related_link#H6475461
Reference: Brown R et al. An evaluation of the DiaMed assays for immunoglobulin A antibodies (anti-IgA) and IgA deficiency. Transfusion 2008; 48(10): 2057-9
15.
A 58-year-old male presents to the ED with RLE pain and swelling. An Ultrasound is performed that reveals a DVT of the right posterior tibial vein. He has recently come back from a long plane ride he took to Asia. This is felt to be a provoked DVT. He is up to date with his age-appropriate cancer screening tests. He has a history of Type II DM and his calculated CrCl=35 mL/min.
Hematology is consulted on this case as he needs to start on anticoagulation, but the patient has a history of HIT that occurred 2 years ago after he received prophylactic enoxaparin during an inpatient admission that he had for pneumonia. However, he did not have any clotting event (no DVT, stroke) with that HIT episode. He just had thrombocytopenia during that time. The HIT Antibody and Serotonin release assay were both positive during that admission.
He needs to be started on anticoagulation for his current RLE DVT. Of the following choices, what is the best option for him?
A . IVC Filter
B . Coumadin 5 mg daily
C . Enoxaparin 1.5 mg/kg x 5 days along with Coumadin 5 mg daily
D . Xarelto 15 mg po bid x 3 weeks then 20 mg po daily
E . Heparin gtt x 5 days along with Coumadin 5 mg daily
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Xarelto 15 mg po bid x 3 weeks then 20 mg po daily
Xarelto is a factor Xa inhibitor.
It is an approved medication that is given in the following situations:
--To reduce the risk of stroke and embolism in patients with nonvalvular atrial fibrillation
--Treatment of a DVT and PE and for the reduction in the risk of recurrence of a DVT and of PE
--DVT prophylaxis for patients who are undergoing knee/hip replacement surgery
Given this patient’s history of HIT, it would not be ideal to rechallenge him with heparin or low-molecular weight heparin.
Coumadin needs several days to become therapeutic and thus the patient would need a bridge with a heparin product for at least 5 days.
One advantage of Xarelto (or any of the Direct Oral anticoagulants) is that no bridging therapy is needed and it can be given as monotherapy. Xarelto has been shown to be an effective medication for those patients with a history of HIT (or who have current HIT).
Mothers who are nursing should discontinue the drug or discontinue nursing. Patients with renal impairment will need to avoid or adjust the dose based on CrCl and treatment indication. Patients with severe hepatic impairment (Child-Pugh B and C hepatic impairment or with any degree of hepatic disease associated with coagulopathy), should avoid using this medication.
For patients being treated for DVT, PE and for the reduction in the risk of recurrence of DVT and of PE, one should avoid Xarelto for patients who have a CrCl <30 mL/min.
Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf
16.
A 68-year-old male has recently been diagnosed with a T2 N0 M0 Urothelial transitional cell cancer. Pathology reveals muscle invasion and he has a Grade 1 tumor. CT C/A/P without contrast shows no signs of distant metastases.
The patient has a long-standing history of Type II DM and HTN. His baseline Creatinine Clearance is 25 ml/min. His case is discussed at tumor board. What treatment should be recommended for him?
A . Neoadjuvant Cisplatin-based chemotherapy followed by a cystectomy
B . Concurrent chemoradiation
C . Cystectomy alone
D . Radiation alone
E . Choice B or C
Your Answer : Option
Not Answered
Correct Answer : Option
E
Explanation:E) Choice B or C
For muscle invasive urothelial cancer (T2, T3, T4), the standard of care is to provide neoadjuvant Cisplatin based chemotherapy (dose-dense MVAC preferred) followed by a cystectomy.
Guidelines have suggested that if a patient with muscle invasive urothelial cancer is not deemed to be a candidate for Cisplatin (ie, renal dysfunction), then he or she should not receive neoadjuvant chemotherapy. Carboplatin for this malignancy is not felt to be adequate treatment.
The data for adjuvant chemotherapy for bladder cancer is less robust. However, guidelines do suggest that for those patients who do not receive neoadjuvant chemotherapy, one can consider offering adjuvant chemotherapy based on post-operative pathology. Patients with a T3 to T4 tumor or positive nodes can be considered for adjuvant chemotherapy.
Of note, if a patient undergoes initial cystectomy and has a tumor that is pT2 or less with no nodal involvement or LVI, then adjuvant chemotherapy is not recommended. This is important as often a Medical Oncologist will see a patient only after the patient has undergone a cystectomy; there was no opportunity to give neoadjuvant chemotherapy.
This patient has a T2 urothelial cancer and is not a candidate for Cisplatin. One would proceed with surgery/cystectomy or concurrent chemoradiation with 5-FU/Mitomycin C (after a maximal debulking TURBT). Concurrent chemoradiation does has Category 1 evidence to offer in this setting as does neoadjuvant Cisplatin-based chemotherapy followed by a radical cystectomy. However, given his renal dysfunction, he is not a candidate for Cisplatin.
The guidelines for Cisplatin dosing based on renal dysfunction are not standard. However, some guidelines recommend the following:
GFR (ml/min) >60 Give 100% of the dose
45-59 Give 75% of the dose
<45 Consider Carboplatin [Depending on the tumor type]
Some will use split dose cisplatin in patients who have a low CrCl. Generally speaking, Cisplatin should not be offered to patients with a CrCl that is < 60 mL/min.
For patients on dialysis, give 50% of the Cisplatin dose. Dialysis should be performed within 3 hours after giving the dose of Cisplatin.
Reference: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
17.
A 14-year-old male has a history of severe Hemophilia A with Factor VIII levels < 1%. He developed right knee bleeding at the age of 1. Since that time, he has been receiving prophylaxis with Factor VIII, 30 units/kg three times a week. Despite this, he still has required many Factor VIII infusions for breakthrough bleeding episodes.
When he was around 8 years old, he was found to have an inhibitor and he has required bypassing agents to control episodes of bleeding. Despite this, he continues to have several bleeds every year especially at his bilateral knees. Which medication should one consider adding at this time as prophylaxis to help control his bleeding?
A . None
B . Factor IX infusions
C . Rituximab
D . IVIG
E . Emicizumab
Your Answer : Option
Not Answered
Correct Answer : Option
E
Explanation:E) Emicizumab
The FDA has approved emicizumab-kxwh for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with and without factor VIII inhibitors.
Emicizumab bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in patients with hemophilia A.
Patients enrolled in the HAVEN 1 study were 12 years of age or older. Those who had previously received episodic treatment with bypassing agents were randomly assigned in a 2:1 ratio to emicizumab prophylaxis (group A) or no prophylaxis (group B). The primary end point was the difference in bleeding rates between group A and group B. Participants who had previously received prophylactic treatment with bypassing agents received emicizumab prophylaxis in group C.
A total of 109 male participants with hemophilia A with inhibitors were enrolled. The annualized bleeding rate was 2.9 events among participants who were randomly assigned to emicizumab prophylaxis versus 23.3 events among those assigned to no prophylaxis. This represents a significant difference of 87% in favor of emicizumab prophylaxis (P<0.001).
A total of 22 participants in group A (63%) had zero bleeding events, as compared with 1 participant (6%) in group B. Among 24 participants in group C who had participated in a noninterventional study, emicizumab prophylaxis resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing-agent prophylaxis (P<0.001).
Overall, 198 adverse events were reported in 103 participants receiving emicizumab prophylaxis; the most frequent events were injection-site reactions (in 15% of participants). Thrombotic microangiopathy and thrombosis were reported in 2 participants each (in the primary analysis) who had received multiple infusions of activated prothrombin complex concentrate for breakthrough bleeding. No antidrug antibodies were detected.
As mentioned above, Emicizumab also has FDA approval in patients with Hemophilia A who do not have an inhibitor.
The HAVEN 3 study tested emicizumab as prophylaxis in 152 patients aged 12 years or older with severe hemophilia A (Factor VIII activity <1%) who did not have an inhibitor. Most of these patients were only receiving episodic therapy fro bleeding.
Compared with controls receiving only episodic therapy with factor VIII, individuals assigned to emicizumab prophylaxis had a dramatically reduced annualized bleeding rate (38 events versus 1.5 and 1.3 events at the two dosing protocols [1.5 mg/kg once weekly or 3 mg/kg every other week, respectively)
All controls had at least one bleeding event during the study (24 weeks), whereas more than half of participants in both emicizumab groups had no bleeding events during the study.
In the group of 48 patients who had been receiving routine factor VIII prophylaxis, transition to emicizumab reduced the annualized bleeding rate by 68 percent.
Johannes Oldenburg et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377:809-818
Reference: Mahlangu J et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018;379(9):811.
18.
A 64-year-old year-old male has recently completed concurrent chemoradiation for his Stage IIIB lung adenocarcinoma. He received Cisplatin/Etoposide during the radiation. He tolerated therapy quite well with no major side effects. A restaging CT scan 4 weeks after completing therapy shows reduction of his tumor mass.No new or distant metastatic disease was seen. Which therapy should be given at this time as part of consolidation therapy?
A . Single agent Alimta
B . Cisplatin and Etoposide x 2 cycles
C . Pembrolizumab
D . Durvalumab
E . Observation
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Durvalumab
Most patients with Stage III unresectable, NSCLC will have subsequent disease progression despite receiving definitive chemoradiotherapy.
The PACIFIC study was a phase 3 study that compared the anti–programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.
Patients were randomly assigned in a 2:1 ratio, to receive durvalumab (10 mg/kg) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy.
Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo).
The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo (HR=0.52; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%.
The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months).
The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively).
A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.
Reference: Scott J. Antonia et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2017; 377:1919-1929
19.
A 62-year-old male presented to see his PCP doctor for a 1-month history of worsening right flank pain. An Ultrasound is order that shows a 2 cm right kidney mass. Subsequently, the patient has a CT C/A/P performed that confirms the Right kidney mass. No other sites of disease are seen. The patient is referred over to see a Urologist.
The patient undergoes a radical nephrectomy. Pathology reveals that the patient has a Stage I, Collecting duct cancer. The patient undergoes close surveillance with imaging. Unfortunately, 1 year later he is found to have widely metastatic disease. A biopsy of a lung lesion reveals a collecting duct cancer. Next generation sequencing reveals no actionable mutations. Which therapy should be offered?
A . Sutent
B . Pazopanib
C . Axitinib
D . Gemzar + Platinum
E . Everolimus
Your Answer : Option
Not Answered
Correct Answer : Option
D
Explanation:D) Gemzar + Platinum
Collecting (Bellini) duct carcinoma is a rare subtype of renal cell cancer. It acts aggressively and it presents symptomatically at an advanced stage. Patients with this malignancy will normally have a poor prognosis. Collecting duct carcinoma shares biologic features with urothelial carcinoma.
For collecting duct or medullary subtype of kidney cancer, partial responses have been observed with cytotoxic chemotherapy (Carboplatin + Gemcitabine, Carboplatin + Paclitaxel, or Cisplatin + Gemcitabine) and other platinum-based chemotherapies currently used for urothelial carcinomas.
One group performed a systematic review of the literature on the management options for collecting duct cancer.
The best studied therapy was felt to be Gemcitabine/Cisplatin. The role of targeted therapy (tyrosine kinase inhibitors such as sunitinib or sorafenib) and immunotherapy in the management of collecting duct carcinoma has not been as well established.
A prospective multicentre phase II study evaluated the efficacy of gemcitabine and either cisplatin or carboplatin on Stage IV collecting duct cancer.
Participants received 21-day cycles of gemcitabine 1250 mg/m2 on days 1 and 8, plus cisplatin or carboplatin 70 mg/m2 (based on renal function) on day 1 (n = 23 gemcitabine, n = 12 cisplatin, n = 6 carboplatin, and n = 5 cisplatin then carboplatin). Participants underwent a median of 6 cycles of treatment (range: 1–8 cycles).
Participating patients achieved a 26% partial or complete response rate with 1 complete response. Another 10 patients (44%) experienced disease stabilization, and 7 had progressive disease (30%). Progression-free survival was 7.1 months and overall survival was 10.5 months.
Reference: S Dason et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol 2013 Jun; 20(3): e223–e232.
20.
A 66-year-old male presents to see a Hematologist/Oncologist for diffuse lymphadenopathy that has slowly developed throughout his body over the past 6 months. His exam reveals lymphadenopathy in his cervical neck, axilla and inguinal area. He has a palpable spleen. He denies having any constitutional B symptoms.
An excisional biopsy is performed of his cervical lymph node. Lymphoma is confirmed. The lymphoma is: CD10-, CD5+, CD23-, Cyclin D1- and SOX11+. His Ki67 is 20%.
A PET-CT is performed that confirms disease throughout his body. What is the most likely lymphoma that this patient has?
A . Follicular lymphoma
B . CLL/SLL
C . Mantle cell lymphoma
D . DLBCL
E . Marginal zone lymphoma
Your Answer : Option
Not Answered
Correct Answer : Option
C
Explanation:C) Mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma defined by cyclin D1 (CCND1) overexpression. The characteristic translocation seen in this lymphoma is t(11;14).
The Mantle Cell Lymphoma International Prognostic Index (MIPI) has been designed to stratify MCL patients into risk groups (low, intermediate or high risk) based on clinical prognostic factors, such as age, performance status, Wbc count and lactate dehydrogenase (LDH) level.
Ki-67 expression over 30% portends a more aggressive clinical course. TP53 expression and blastoid subtype are also associated with Mantle cell displaying an aggressive behavior.
In addition to CCND1, SOX11 is a diagnostic antigen in MCL. Cyclin D1- (CCND1 negative) mantle cell lymphomas are not well characterized. SOX11 has been identified recently as a reliable biomarker of MCL that is also expressed in the cyclin D1 negative variant. Data sets have demonstrated that Cyclin D1 negative MCL patients are clinically and biologically similar to the conventional cyclin D1(+) MCL.
The most common biomarker for indolent disease:
SOX11- [IGHV mutated]
Typical clinical presentation:
Leukemic non-nodal CLL-like with splenomegaly, low tumor burden, Ki67 proliferation fraction <10%
Reference: Lena Nordström et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. Br J Haematol 2014 Jul; 166(1): 98–108